

[Return to CIRM Meetings and Events](#)

## Use of Induced Pluripotent Stem Cells as Screening Tools and Therapeutics Presentations from FDA and Leading Experts



### Use of Induced Pluripotent Stem Cells as Screening Tools and Therapeutics

#### Presentations from FDA and Leading Experts

This webinar was held on September 11, 2014

Slide decks and a recording of the webinar are now available (see below).

#### WEBINAR TOPIC & AGENDA

##### MODERATOR:

Ellen Feigal, MD, Senior Vice President of Research and Development, CIRM

##### Speakers:

- **Keith Wonnacott**, Ph.D., Chief, Cellular Therapies Branch, Office of Cellular, Tissue and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
- **Steve Finkbeiner**, MD, Ph.D., Professor, Departments of Neurology and Physiology, University of California, San Francisco
- **Kyle Kolaja**, Ph.D., Vice President, Business Development, Cellular Dynamics
- **Melissa Carpenter**, Ph.D., Principal, Carpenter Group Consulting

##### Topics to be covered:

The focus of this webinar is on the use of Induced Pluripotent Stem Cells (iPSCs)– used as a tool for disease modeling, target identification, or toxicity assessment, or as a cell therapy intervention. Speakers will cover preclinical and manufacturing regulatory challenges in moving an iPSC forward as a cell therapy, and challenges along the regulatory pathway in use of iPSCs as tools.

- Presentation by FDA - Donor Eligibility and the testing required for iPSCs and hESCs
- Lessons learned and regulatory issues for use of iPSC for tools and therapies

- Questions and Answers

**Resources:**

Link to Webinar Recording

Question & Answers from September 11, 2014 iPSC Webinar

**Slide Decks of Presentations:**

Kyle Kolaja: Humanizing the Tissue Chip: Use of Stem Cell Derived Tissues to Develop Biological Platforms [pdf]

Melissa Carpenter: Preclinical Development of iPSC Therapies [pdf]

Keith Wonnacott: Donor Eligibility and Testing of iPSCs and hESCs For Therapeutic Use [pdf]

Steven Finkbeiner: Patient-Derived Induced Pluripotent Stem Cells as a Therapeutics Discovery Platform: Challenges and Opportunities [pdf]

---

**Source URL:** <http://www.cirm.ca.gov/agendas/08182014/use-induced-pluripotent-stem-cells-screening-tools-and-therapeutics-presentations>